A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib

被引:18
作者
Crossman, LC
O'Hare, T
Lange, T
Willis, SG
Stoffregen, EP
Corbin, AS
O'Brien, SG
Heinrich, MC
Druker, BJ
Middleton, PG
Deininger, MWN
机构
[1] Newcastle Univ, Acad Haematol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97201 USA
[3] Univ Leipzig, Dept Haematol Oncol, D-7010 Leipzig, Germany
关键词
CML; imatinib; polymorphism; ABL; dasatinib;
D O I
10.1038/sj.leu.2403935
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have identified a gene polymorphism (K247R) within or close to the P-loop of BCR-ABL, which leads to the substitution of arginine for lysine. We investigated the allelic frequency of K247R by screening 157 CML patients and 213 healthy blood donors with conventional sequencing, restriction enzyme digest and single strand conformational polymorphism analysis, and found the arginine allele to be rare. Three out of five CML patients with the arginine allele of K247R failed to achieve a major cytogenetic response to imatinib, suggesting that the arginine allele may have reduced sensitivity. However, despite K247R's position in or near to the P-loop, biochemical and cellular assays of imatinib and dasatinib sensitivity showed no alteration compared to wild type. Clinicians should be aware that possession of the arginine allele of K247R does not reflect a mutation that necessitates a change in the therapeutic strategy, unless there are other signs of inadequate response to drug.
引用
收藏
页码:1859 / 1862
页数:4
相关论文
共 21 条
[1]   High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib [J].
Al-Ali, HK ;
Heinrich, MC ;
Lange, T ;
Krahl, R ;
Mueller, M ;
Müller, C ;
Niederwieser, D ;
Druker, BJ ;
Deininger, MWN .
HEMATOLOGY JOURNAL, 2004, 5 (01) :55-60
[2]   Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL [J].
Azam, M ;
Latek, RR ;
Daley, GQ .
CELL, 2003, 112 (06) :831-843
[3]   Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].
Branford, S ;
Rudzki, Z ;
Walsh, S ;
Parkinson, I ;
Grigg, A ;
Szer, J ;
Taylor, K ;
Herrmann, R ;
Seymour, JF ;
Arthur, C ;
Joske, D ;
Lynch, K ;
Hughes, T .
BLOOD, 2003, 102 (01) :276-283
[4]   Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571 [J].
Corbin, AS ;
Buchdunger, E ;
Pascal, F ;
Druker, BJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (35) :32214-32219
[5]   Several Bcr-Ab1 kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib [J].
Corbin, AS ;
La Rosée, P ;
Stoffregen, EP ;
Druker, BJ ;
Deininger, MW .
BLOOD, 2003, 101 (11) :4611-4614
[6]   The development of imatinib as a therapeutic agent for chronic myeloid leukemia [J].
Deininger, M ;
Buchdunger, E ;
Druker, BJ .
BLOOD, 2005, 105 (07) :2640-2653
[7]   The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells [J].
Deininger, MWN ;
Goldman, JM ;
Lydon, N ;
Melo, JV .
BLOOD, 1997, 90 (09) :3691-3698
[8]  
FAINSTEIN E, 1989, ONCOGENE, V4, P1477
[9]   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].
Gorre, ME ;
Mohammed, M ;
Ellwood, K ;
Hsu, N ;
Paquette, R ;
Rao, PN ;
Sawyers, CL .
SCIENCE, 2001, 293 (5531) :876-880
[10]   Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy [J].
Hochhaus, A ;
Kreil, S ;
Corbin, AS ;
La Rosée, P ;
Müller, MC ;
Lahaye, T ;
Hanfstein, B ;
Schoch, C ;
Cross, N ;
Berger, U ;
Gschaidmeier, H ;
Druker, BJ ;
Hehlmann, R .
LEUKEMIA, 2002, 16 (11) :2190-2196